avedaa.blogg.se - I doser free download all doses

in persons who have received a Vaxzevria vaccination, including persons who, following a 1st dose of Vaxzevria vaccine, have developed a deep thromboembolic syndrome with thrombocytopenia.

The use of Nuvaxovid vaccine is permitted as part of a heterologous ("mix-and-match") vaccine pattern, and in particular (CSMI recommendations of July 2021 and March 2022):

as a heterologous booster dose for anyone who has experienced medically significant side effects after primary vaccination with mRNA or viral vector vaccines.

as a homologous booster dose for all persons receiving a full primary vaccination with Nuvaxovid, starting 3 months after the last dose.

as an extra dose (booster) after a single dose of COVID-19 Vaccine JCOVDEN, starting 28 days after vaccination with COVID-19 Vaccine JCOVDEN.as a 3rd dose as part of a primary vaccination (with Nuvaxovid) for immunocompromised persons, persons receiving organ transplants and persons undergoing renal dialysis (CSMI recommendations of December 2021 and January 2022), according to a schedule at 0, 28 and 84 days (0, 4 and 12 weeks).Nuvaxovid vaccine can be used for the COVID-19 vaccination of adults aged 18 years or older, according to a primary vaccination of 2 doses of 5 μg (0.5 ml), with an interval of 28 days. The list of doctors and pharmacies participating in the vaccination campaign are available on the website. Those concerned can go to a doctor or a pharmacy to be vaccinated. a complete vaccination schedule with the single-dose JCOVDEN vaccine (Johnson & Johnson) + 1 booster dose. a complete vaccination schedule with a 2-dose vaccine + 1 "booster" dose or In addition, to be eligible for this 2nd booster dose, the person must have received : This booster dose is intended to maintain the high level of vaccine protection that these individuals have acquired against infection, severe disease and death. The vaccine product used is a bivalent messenger RNA vaccine (Comirnaty Wuhan/B.A.1 or Spikevax Wuhan/B.A.1 or Comirnaty Wuhan/B.A. The 4th dose is given at an interval of at least 4 months after the booster dose (3rd vaccination dose). However, this 4th dose is not recommended for healthy individuals who have had an SARS-CoV-2 infection (confirmed by PCR or antigen test) after the first booster dose. The 2nd booster dose can also be offered on an individual basis to all other persons aged 12 to 59 years without risk factors and who have not had a recent infection. persons between 12 and 59 years of age with co-morbidities that put them at risk for severe forms of COVID-19,.Who is elligible for a 4th dose of the vaccine?Īccording to the recommendation of the Higher Council for Infectious Diseases (CSMI), a 4th dose of COVID-19 vaccine is recommended for the following persons